All stock lists
Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
Healthcare · Biotechnology
6.00+0.26 (+4.53%)
Insider Score
––Not scored
PHAT Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
PHAT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 74.27 M | 58.30 M | 57.58 M | 49.50 M | 39.50 M |
| Revenue Growth (YoY) | 88.02 % | — | — | — | — |
| Cost of Revenue | 15.10 M | 12.00 M | 7.65 M | 6.19 M | 5.04 M |
| Gross Profit | 59.18 M | 46.30 M | 49.94 M | 43.31 M | 34.47 M |
| SG&A Expense | 55.33 M | 54.01 M | 48.37 M | 51.56 M | 85.31 M |
| R&D Expense | 7.81 M | 7.77 M | 7.49 M | 7.03 M | 9.08 M |
| Operating Expenses | 63.14 M | 61.78 M | 55.86 M | 58.59 M | 94.39 M |
| Operating Income | -3.96 M | -15.48 M | -5.93 M | -15.27 M | -59.92 M |
| Pretax Income | -17.58 M | -30.37 M | -21.15 M | -29.97 M | -75.81 M |
| Tax Provision | — | — | — | — | — |
| Net Income | -17.58 M | -30.37 M | -21.15 M | -29.97 M | -75.81 M |
| EPS (Basic) | -0.21 | -0.37 | -0.29 | -0.41 | -1.05 |
| EPS (Diluted) | -0.21 | -0.37 | -0.29 | -0.41 | -1.05 |
| Shares Outstanding | 83.75 M | 82.05 M | 73.82 M | 73.40 M | 72.47 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.